Targeted p53 Reactivation in TP53 Y220C-Mutated Malignancies: Phase I Clinical Trial Results of Rezatapopt
A phase I dose-escalation study of rezatapopt demonstrated preliminary antitumor activity in patients with TP53 Y220C-mutated solid tumors, representing the first clinical validation of mutation-specific p53 reactivation therapy.